Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Intensity-modulated radiation therapy as primary treatment for oropharyngeal squamous cell carcinoma.

May JT, Rao N, Sabater RD, Boutrid H, Caudell JJ, Merchant F, Han G, Padhya TA, McCaffrey JC, Tanvetyanon T, Deconti R, Kish J, McCaffrey TV, Trotti A.

Head Neck. 2013 Dec;35(12):1796-800. doi: 10.1002/hed.23245. Epub 2013 Mar 6.

PMID:
23468387
2.

Bilateral orbital vasculature alterations after systemic chemotherapy and external beam radiation therapy treatment of advanced retinoblastoma: implications for intraarterial chemotherapy management.

Boutrid H, Wolfe SQ, Murray TG, Pina Y, Moftakhar R, Fernandes CE, Reichbach J, Aziz-Sultan MA.

Retin Cases Brief Rep. 2011 Spring;5(2):124-7. doi: 10.1097/ICB.0b013e3181c5999c.

PMID:
25389879
3.

Novel retinoblastoma treatment avoids chemotherapy: the effect of optimally timed combination therapy with angiogenic and glycolytic inhibitors on LH(BETA)T(AG) retinoblastoma tumors.

Houston SK, Piña Y, Murray TG, Boutrid H, Cebulla C, Schefler AC, Shi W, Celdran M, Feuer W, Merchan J, Lampidis TJ.

Clin Ophthalmol. 2011 Jan 27;5:129-37. doi: 10.2147/OPTH.S15179.

4.

Medulloepithelioma: invasive versus noninvasive diagnostic methods and their impacts on outcome.

Gologorsky D, Schefler AC, Williams BK Jr, Boutrid H, Dubovy SR, Murray TG.

Retin Cases Brief Rep. 2011 Winter;5(1):33-6. doi: 10.1097/ICB.0b013e3181babe22.

PMID:
25389679
5.

Ophthalmic vasculature alterations following systemic chemotherapy and periocular Carboplatin treatment of advanced retinoblastoma.

Piña Y, Boutrid H, Murray TG, Wolfe SQ, Schefler AC, Houston SK, Moftakhar R, Fernandes CE, Reichbach J, Aziz HA, Markoe AM, Aziz-Sultan MA.

J Pediatr Ophthalmol Strabismus. 2010 Sep 22;47 Online:e1-5. doi: 10.3928/01913913-20100920-04.

PMID:
20886809
6.

Focal, periocular delivery of 2-deoxy-D-glucose as adjuvant to chemotherapy for treatment of advanced retinoblastoma.

Piña Y, Houston SK, Murray TG, Boutrid H, Celdran M, Feuer W, Shi W, Hernandez E, Lampidis TJ.

Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6149-56. doi: 10.1167/iovs.09-5033. Epub 2010 Aug 11.

7.

Supraselective injection of intraarterial melphalan as the primary treatment for late presentation unilateral multifocal stage Vb retinoblastoma.

Aziz HA, Boutrid H, Murray TG, Berrocal A, Wolfe SQ, Pina Y, Dorfman M, Moftakhar R, Fernandes CE, Reichbach J, Aziz-Sultan MA.

Retina. 2010 Apr;30(4 Suppl):S63-5. doi: 10.1097/IAE.0b013e3181cbda0f.

PMID:
20224464
8.

Impact of tumor-associated macrophages in LH(BETA)T(AG) mice on retinal tumor progression: relation to macrophage subtype.

Piña Y, Boutrid H, Murray TG, Jager MJ, Cebulla CM, Schefler A, Ly LV, Alegret A, Celdran M, Feuer W, Jockovich ME.

Invest Ophthalmol Vis Sci. 2010 May;51(5):2671-7. doi: 10.1167/iovs.09-4255. Epub 2010 Jan 6.

9.

Increased hypoxia following vessel targeting in a murine model of retinoblastoma.

Boutrid H, Piña Y, Cebulla CM, Feuer WJ, Lampidis TJ, Jockovich ME, Murray TG.

Invest Ophthalmol Vis Sci. 2009 Dec;50(12):5537-43. doi: 10.1167/iovs.09-3702. Epub 2009 Jul 2.

PMID:
19578014
10.

Blood vessel maturation in human uveal melanoma: spatial distribution of neovessels and mature vasculature.

Piña Y, Cebulla CM, Murray TG, Alegret A, Dubovy SR, Boutrid H, Feuer W, Mutapcic L, Jockovich ME.

Ophthalmic Res. 2009;41(3):160-9. doi: 10.1159/000209670. Epub 2009 Mar 26.

11.

Blood vessel maturation in retinoblastoma tumors: spatial distribution of neovessels and mature vessels and its impact on ocular treatment.

Piña Y, Boutrid H, Schefler A, Dubovy S, Feuer W, Jockovich ME, Murray TG.

Invest Ophthalmol Vis Sci. 2009 Mar;50(3):1020-4. doi: 10.1167/iovs.08-2654. Epub 2008 Oct 24.

PMID:
18952925
12.

Basic fibroblast growth factor impact on retinoblastoma progression and survival.

Cebulla CM, Jockovich ME, Piña Y, Boutrid H, Alegret A, Kulak A, Hackam AS, Bhattacharya SK, Feuer WJ, Murray TG.

Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5215-21. doi: 10.1167/iovs.07-1668. Epub 2008 Jul 9.

13.

Targeting hypoxia, a novel treatment for advanced retinoblastoma.

Boutrid H, Jockovich ME, Murray TG, Piña Y, Feuer WJ, Lampidis TJ, Cebulla CM.

Invest Ophthalmol Vis Sci. 2008 Jul;49(7):2799-805. doi: 10.1167/iovs.08-1751. Epub 2008 Mar 7.

PMID:
18326690
14.

Lack of effect of SU1498, an inhibitor of vascular endothelial growth factor receptor-2, in a transgenic murine model of retinoblastoma.

Cebulla CM, Jockovich ME, Boutrid H, Piña Y, Ruggeri M, Jiao S, Bhattacharya SK, Feuer WJ, Murray TG.

Open Ophthalmol J. 2008 Apr 2;2:62-7. doi: 10.2174/1874364100802010062.

Supplemental Content

Loading ...
Support Center